Navigation Links
Bayer HealthCare Selects the State of New Jersey for East Coast Site Consolidation
Date:4/4/2011

WAYNE, N.J., April 4, 2011 /PRNewswire/ -- Bayer HealthCare and the Governor of New Jersey, Chris Christie, are proud to announce that the company has selected New Jersey as the new "home" of Bayer HealthCare's consolidated East-Coast business site.  

"We are very excited about the prospect of having a new site and facility that can house East Coast-based Bayer HealthCare employees from every division and function under one roof," said Mark Trudeau, President and CEO, Bayer HealthCare Pharmaceuticals Inc., Bayer HealthCare LLC USA and chair of the company's U.S. East Coast Site Search Committee. "New Jersey is home to many bio-pharmaceutical and healthcare companies, and we look forward to benefiting from the many resources and opportunities available to us in the state."  

Commenting on the company's decision, Governor Chris Christie said, "Bayer's commitment to stay and expand in New Jersey is another signal that our state is growing and that this administration's job creating policies are paying dividends.  Bayer's planned investment in New Jersey will help keep us the premier state in the nation for the pharmaceutical industry in addition to creating needed jobs and giving a boost to our state's economy."  

Although a specific location has not yet been chosen, several sites near the company's existing New Jersey locations are now under consideration. A final decision on the site is expected to be made within the next few months.  Between its divisions and corporate functions the company employs approximately 2,500 people in the New Jersey and New York area. First moves are expected to occur in late 2011/early 2012 and proceed through the end of 2013.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, is one of the world's leading, innovative companies
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... a special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates ... continue highlighting the success of the prescription drug benefit, commonly referred to as Part ... infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... SEATTLE, Feb. 10 Cell Therapeutics (CTI) (NASDAQ and ... definitive collaborative agreement with IDIS to manage its investigational ... Pixantrone will be supplied by IDIS to healthcare ... aggressive non-Hodgkin,s lymphoma. This program is expected to ...
... MONTREAL, Feb. 9 Sequoia Pharmaceuticals presented,positive ... in healthy volunteers and,preclinical studies on SPI-452, ... antiviral activity. Pharmacokinetic enhancers increase drug levels ... (CYP)-mediated,drug metabolism. These increased drug levels can ...
Cached Medicine Technology:Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 2Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 3Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 4Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone 5Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 2Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 3Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 4Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer 5
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Precision Aesthetics ... eight years. It was also the first provider of Exilis non-surgical fat reduction ... sought after procedures it has attracted a large International clientele. Many patients travel ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator ... new applicator in the United States as an upgrade to the CoolSmooth applicator cleared ... applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... uterus, the more likely she is to have a miscarriage, ... Journal of Medicine details the most precise information the timing ... its success or failure. ,Fertilised eggs can attach themselves ... 12 days after ovulation, the researchers from the National Institute ...
... the chances of getting bowel cancer, say scientists. Swedish ... and say that it points more firmly than ever to ... Research Campaing and Swedish Cancer Foundation, combined and analysed the ... It found that people who exercised regulatly were 50% less ...
... resposible for infertility.The virus is called adeno-associated virus (AAV) ... from men whose semen was abnormal. The virus was ... those with normal semen. ,Dr Jorg Schlehofer, ... research, said the virus should be assessed further to ...
... blood disorder that affects red blood cells. People with ... an abnormal type of hemoglobin. Sometimes these red blood ... blood vessels. When sickle-shaped cells clump together and obstruct ... to require hospital admission. // ,Researchers from ...
... among the deadliest of cancers, affecting many people a year ... the most aggressive cancer and there are few palliative treatments. ... deadly pancreatic cancer cells in the test tube and in ... Dr. Paul B. Fisher, a professor of clinical pathology at ...
... widely used anticancer drug, hydroxyurea, shows potent colon cancer-killing ... researchers. The new compounds seem to be very interesting ... ,Previous drugs derived from hydroxyurea were extremely active in ... serious side effects. This prompted the researchers to synthesize ...
Cached Medicine News:
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
... superb radiation protection-0.62mm (+/- .05)Pb lead glass ... to their level of protection, they are ... smoothly on your bridge while hugging your ... wear corrective lenses, you can order Leaded ...
Medicine Products: